Published online before print
May 31, 2006 Eur Respir J 2006, doi:10.1183/09031936.06.00001506
Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages
S. Hodge 1*,
G. Hodge 1,
S. Brozyna 1,
H. Jersmann 1,
M. Holmes 1,
P.N. Reynolds 1
1 Dept of Thoracic Medicine, Royal Adelaide Hospital and Lung Research Laboratory, Hanson Institute, Adelaide, South Australia
* To whom correspondence should be addressed. E-mail: sandy.hodge{at}imvs.sa.gov.au.
 |
Abstract |
|---|
Chronic obstructive pulmonary disease (COPD) is associated with increased apoptosis and defective phagocytosis in the airway. As uncleared cells can undergo secondary necrosis and perpetuate inflammation, strategies to improve clearance would have therapeutic significance. There is evidence that the 15-member macrolide antibiotic azithromycin has anti-inflammatory properties. Its effects may be increased in the lung due to its ability to reach high concentrations in alveolar macrophages (AM). This study investigated the effects of low-dose (500 ng·ml-1) azithromycin on phagocytosis of apoptotic bronchial epithelial cells and neutrophils by AM. Flow cytometry was applied to measure phagocytosis and receptors involved in AM recognition of apoptotic cells. Cytokines were investigated using cytometric bead array. Baseline phagocytosis was reduced in COPD subjects compared to controls. Azithromycin significantly improved the phagocytosis of epithelial cells or neutrophils by AM from COPD subjects by 68% and 38% respectively, often up to levels comparable to controls. The increase in phagocytosis was partially inhibited by phosphatidylserine (PS), implicating the PS pathway in the pro-phagocytic effects of azithromycin. Azithromycin had no effect on other recognition molecules (GM-CSF, CD44, CD31, CD36, CD91, v 3integrin). At higher doses azithromycin decreased levels of pro-inflammatory cytokines. Low-dose azithromycin therapy could thus provide an adjunct therapeutic option in COPD.
Keywords:
Alveolar macrophage, apoptosis, azithromycin, COPD, phagocytosis
This article has been cited by other articles:

|
 |

|
 |
 
T. R. Richens, D. J. Linderman, S. A. Horstmann, C. Lambert, Y.-Q. Xiao, R. L. Keith, D. M. Boe, K. Morimoto, R. P. Bowler, B. J. Day, et al.
Cigarette Smoke Impairs Clearance of Apoptotic Cells through Oxidant-dependent Activation of RhoA
Am. J. Respir. Crit. Care Med.,
June 1, 2009;
179(11):
1011 - 1021.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. F Idris, E. R Chilvers, C. Haworth, D. McKeon, and A. M Condliffe
Azithromycin therapy for neutrophilic airways disease: myth or magic?
Thorax,
March 1, 2009;
64(3):
186 - 189.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kazeros, B.-G. Harvey, B. J. Carolan, H. Vanni, A. Krause, and R. G. Crystal
Overexpression of Apoptotic Cell Removal Receptor MERTK in Alveolar Macrophages of Cigarette Smokers
Am. J. Respir. Cell Mol. Biol.,
December 1, 2008;
39(6):
747 - 757.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Hodge, G. Hodge, H. Jersmann, G. Matthews, J. Ahern, M. Holmes, and P. N. Reynolds
Azithromycin Improves Macrophage Phagocytic Function and Expression of Mannose Receptor in Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med.,
July 15, 2008;
178(2):
139 - 148.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Braganza, R. Chaudhuri, and N. C. Thomson
Review: Treating patients with respiratory disease who smoke
Therapeutic Advances in Respiratory Disease,
April 1, 2008;
2(2):
95 - 107.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
B. S. Murphy, V. Sundareshan, T. J. Cory, D. Hayes Jr, M. I. Anstead, and D. J. Feola
Azithromycin alters macrophage phenotype
J. Antimicrob. Chemother.,
March 1, 2008;
61(3):
554 - 560.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Simpson, H. Powell, M. J. Boyle, R. J. Scott, and P. G. Gibson
Clarithromycin Targets Neutrophilic Airway Inflammation in Refractory Asthma
Am. J. Respir. Crit. Care Med.,
January 15, 2008;
177(2):
148 - 155.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. D. Starner, J. D. Shrout, M. R. Parsek, P. C. Appelbaum, and G. Kim
Subinhibitory Concentrations of Azithromycin Decrease Nontypeable Haemophilus influenzae Biofilm Formation and Diminish Established Biofilms
Antimicrob. Agents Chemother.,
January 1, 2008;
52(1):
137 - 145.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Hodge, G. Hodge, J. Ahern, H. Jersmann, M. Holmes, and P. N. Reynolds
Smoking Alters Alveolar Macrophage Recognition and Phagocytic Ability: Implications in Chronic Obstructive Pulmonary Disease
Am. J. Respir. Cell Mol. Biol.,
December 1, 2007;
37(6):
748 - 755.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2006 by the European Respiratory Society.
|